Global X Japan Co. Ltd. Grows Stake in Gilead Sciences, Inc. $GILD

Global X Japan Co. Ltd. increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5,517.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,234 shares of the biopharmaceutical company’s stock after purchasing an additional 11,034 shares during the quarter. Global X Japan Co. Ltd.’s holdings in Gilead Sciences were worth $1,247,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of GILD. Rothschild Investment LLC lifted its stake in Gilead Sciences by 1.9% in the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after buying an additional 84 shares in the last quarter. Ignite Planners LLC raised its position in shares of Gilead Sciences by 1.1% in the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after buying an additional 86 shares during the period. Archer Investment Corp boosted its holdings in Gilead Sciences by 1.2% in the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after acquiring an additional 87 shares during the last quarter. Binnacle Investments Inc grew its position in Gilead Sciences by 14.3% during the second quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 88 shares during the period. Finally, EPG Wealth Management LLC grew its position in Gilead Sciences by 2.0% during the second quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock valued at $513,000 after acquiring an additional 89 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $125.19 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $88.57 and a 52 week high of $128.70. The company has a market cap of $155.32 billion, a P/E ratio of 19.41, a PEG ratio of 0.69 and a beta of 0.32. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The business has a 50 day moving average of $122.61 and a two-hundred day moving average of $116.40.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same period in the previous year, the business posted $2.02 EPS. Gilead Sciences’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.5%. Gilead Sciences’s payout ratio is 48.99%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GILD. Morgan Stanley lifted their price objective on Gilead Sciences from $147.00 to $151.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Argus lifted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research report on Friday, October 31st. Sanford C. Bernstein reissued an “outperform” rating on shares of Gilead Sciences in a research note on Monday, November 3rd. Finally, HSBC lifted their target price on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $131.54.

Insider Activity at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the transaction, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of the firm’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.10, for a total value of $356,515.50. Following the sale, the director owned 1,339 shares of the company’s stock, valued at $170,186.90. The trade was a 67.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 136,257 shares of company stock valued at $16,723,492 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.